These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 23331529)

  • 1. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
    Shapiro RS
    Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis.
    Shapiro RS
    Ann Allergy Asthma Immunol; 2013 Jul; 111(1):51-5. PubMed ID: 23806460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push.
    Shapiro R
    Clin Exp Immunol; 2013 Aug; 173(2):365-71. PubMed ID: 23607310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis.
    Shapiro R
    J Clin Immunol; 2010 Mar; 30(2):301-7. PubMed ID: 20082124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.
    Stein MR; Koterba A; Rodden L; Berger M
    Postgrad Med; 2011 Sep; 123(5):186-93. PubMed ID: 21904101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.
    Berger M; Rojavin M; Kiessling P; Zenker O
    Clin Immunol; 2011 May; 139(2):133-41. PubMed ID: 21353644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.
    Berger M; Murphy E; Riley P; Bergman GE;
    South Med J; 2010 Sep; 103(9):856-63. PubMed ID: 20689467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents' / caregivers' satisfaction.
    Lechanska-Helman J; Sobocinska A; Jerzynska J; Stelmach I
    Pediatr Int; 2020 Mar; 62(3):316-318. PubMed ID: 31880367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.
    Jolles S; Sleasman JW
    Adv Ther; 2011 Jul; 28(7):521-33. PubMed ID: 21681653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin.
    Milota T; Bloomfield M; Kralickova P; Jilek D; Novak V; Litzman J; Posova H; Mrazova L; Poloniova J; Prucha M; Rozsival P; Rauschova V; Philipp G; Sediva A
    Clin Ther; 2019 Nov; 41(11):2231-2238. PubMed ID: 31564514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulin replacement treatment by rapid subcutaneous infusion.
    Gaspar J; Gerritsen B; Jones A
    Arch Dis Child; 1998 Jul; 79(1):48-51. PubMed ID: 9771252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Subcutaneous gammaglobulin in common variable immunodeficiency. First experience in Spain].
    Maroto Hernando M; Soler Palacín P; Martin Nalda N; Oliveras Arenas M; Español Boren T; Figueras Nadal C
    An Pediatr (Barc); 2009 Feb; 70(2):111-9. PubMed ID: 19217565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
    Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
    Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency.
    Gupta S; Kobayashi RH; Litzman J; Cherwin L; Hoeller S; Kreuwel H
    Expert Rev Clin Immunol; 2023 Jan; 19(1):7-17. PubMed ID: 36346032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina.
    Bezrodnik L; Gómez Raccio A; Belardinelli G; Regairaz L; Díaz Ballve D; Seminario G; Moreira I; Riganti C; Cantisano C; Díaz H; Di Giovanni D
    J Clin Immunol; 2013 Oct; 33(7):1216-22. PubMed ID: 23846854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Subcutaneous immunoglobulin substitution and therapy].
    Gulácsy V; Maródi L
    Orv Hetil; 2011 Jan; 152(2):64-7. PubMed ID: 21177233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of subcutaneous immunoglobulin by rapid "push" infusion for primary immunodeficiency patients in Manitoba: a retrospective review.
    Walter G; Kalicinsky C; Warrington R; Miguel M; Reyes J; Rubin TS
    Allergy Asthma Clin Immunol; 2020; 16():34. PubMed ID: 32426003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose.
    Berger M
    Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):532-8. PubMed ID: 21971330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.
    Kearns S; Kristofek L; Bolgar W; Seidu L; Kile S
    J Manag Care Spec Pharm; 2017 Apr; 23(4):400-406. PubMed ID: 28345437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies.
    Soler-Palacín P; Gasó-Gago I; Fernández-Polo A; Martín-Nalda A; Oliveras M; Martinez-Cutillas J; Figueras C
    J Clin Immunol; 2014 Nov; 34(8):1015-7. PubMed ID: 25190197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.